Literature DB >> 16258096

Length of stay and mortality associated with febrile neutropenia among children with cancer.

Swati K Basu1, Isabel D Fernandez, Susan G Fisher, Barbara L Asselin, Gary H Lyman.   

Abstract

PURPOSE: The aim of this study was to evaluate risk factors for longer length of stay (los) and mortality among hospitalized children with cancer who have febrile neutropenia.
METHODS: This study involved analysis of longitudinal data from the University HealthSystem Consortium database from 1995 to 2002. All patients who were 21 years or younger, with diagnostic codes for both neoplastic disease and febrile neutropenia at discharge, were included.
RESULTS: A total of 12,446 patients were identified for the study. The los was 5 days or less for 6,799 patients, and greater than 5 days for 5,647 patients. The mortality rate was 3%. On bivariate analysis, race, age, cancer type, and associated complications (bacteremia/sepsis, hypotension, pneumonia, and fungal infections) were significantly associated with longer length of stay and death. On multivariate analysis, age group, race, cancer type (acute myeloid leukemia, multiple cancers v acute lymphoblastic leukemia), and the complication variables were significantly associated with increased risk of longer los and death. Certain types of cancer (Hodgkin's disease, osteosarcoma/Ewing's sarcoma, rhabdomyosarcoma, compared with acute lymphoblastic leukemia) and year of discharge after 1995 were significantly associated with a reduced risk of longer length of stay and/or mortality.
CONCLUSION: Race, age group, year of discharge, associated complications, and cancer type were significantly associated with risk of longer los and mortality. These factors may potentially help in identifying high-risk patients who might benefit from targeted antibiotic therapy or prophylactic hematopoietic growth factor support.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258096     DOI: 10.1200/JCO.2005.01.6378

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  27 in total

1.  Effect of Nigella sativa seed administration on prevention of febrile neutropenia during chemotherapy among children with brain tumors.

Authors:  HebatAlla Fathi Mohamed Mousa; Nesrin Kamal Abd-El-Fatah; Olfat Abdel-Hamid Darwish; Shehata Farag Shehata; Shady Hassan Fadel
Journal:  Childs Nerv Syst       Date:  2017-03-27       Impact factor: 1.475

2.  Why pediatric patients with cancer visit the emergency department: United States, 2006-2010.

Authors:  Emily L Mueller; Amber Sabbatini; Achamyeleh Gebremariam; Rajen Mody; Lillian Sung; Michelle L Macy
Journal:  Pediatr Blood Cancer       Date:  2014-10-24       Impact factor: 3.167

3.  Clinical efficacy of adjunctive G-CSF on solid tumor and lymphoma patients with established febrile neutropenia.

Authors:  Alexandre Chan; Qi Xuan Wong; Mohamed Karah Ali; Mabel Wong; Li Yang Hsu
Journal:  Support Care Cancer       Date:  2013-12-07       Impact factor: 3.603

4.  Management of fever and neutropenia in children with cancer.

Authors:  A Vedi; V Pennington; M O'Meara; K Stark; A Senner; P Hunstead; K Adnum; W Londall; L Maurice; Claire Wakefield; R J Cohn
Journal:  Support Care Cancer       Date:  2014-12-23       Impact factor: 3.603

5.  Can complications in febrile neutropenia be predicted? Report from a developing country.

Authors:  Sapna Oberoi; Anirban Das; Amita Trehan; Pallab Ray; Deepak Bansal
Journal:  Support Care Cancer       Date:  2017-06-11       Impact factor: 3.603

6.  Evaluation of predictors of adverse outcome in febrile neutropenic episodes in pediatric oncology patients.

Authors:  Meenakshi Bothra; Rachna Seth; Arti Kapil; S N Dwivedi; Shinjini Bhatnagar; Immaculata Xess
Journal:  Indian J Pediatr       Date:  2012-12-21       Impact factor: 1.967

7.  Repeating blood cultures in neutropenic children with persistent fevers when the initial blood culture is negative.

Authors:  Jeremy Rosenblum; Juan Lin; Mimi Kim; Adam S Levy
Journal:  Pediatr Blood Cancer       Date:  2012-10-09       Impact factor: 3.167

Review 8.  Systematic review of reduced therapy regimens for children with low risk febrile neutropenia.

Authors:  Jessica E Morgan; Jemma Cleminson; Karl Atkin; Lesley A Stewart; Robert S Phillips
Journal:  Support Care Cancer       Date:  2016-01-13       Impact factor: 3.603

9.  Evaluation of febrile neutropenic attacks of pediatric hematology-oncology patients.

Authors:  Yeter Düzenli Kar; Zeynep Canan Özdemir; Özcan Bör
Journal:  Turk Pediatri Ars       Date:  2017-12-01

10.  Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer.

Authors:  Peter de Blank; Theoklis Zaoutis; Brian Fisher; Andrea Troxel; Jason Kim; Richard Aplenc
Journal:  J Pediatr       Date:  2013-03-08       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.